Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Prime Bio Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is being handled by 1 distinct examiner. The prosecution is located within 1 distinct art unit, reflecting a very specific technical focus for the company's current patent activity. This alignment ensures that the application is being reviewed within a specialized group dedicated to its specific biological field.
GRASER, JENNIFER E is the busiest examiner for the portfolio, managing the 1 pending office action. As there is only 1 pending office action in total, GRASER, JENNIFER E is the sole examiner responsible for the company's current pending matters. This 1 pending action represents the entirety of the portfolio's active office actions, making her review critical to the company's immediate success.
The concentration in 1 distinct art unit and the involvement of only 1 distinct examiner simplifies the current prosecution landscape for the company. GRASER, JENNIFER E's role is central, as she oversees the only 1 pending office action. The biotechnology focus is contained within this single examiner's review of the 1 total pending action, allowing for a highly focused response strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASER, JENNIFER E | 1 | 76.9% | +23.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19017741 | TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE | GRASER, JENNIFER E | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19017741 | TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE | GRASER, JENNIFER E | 1645 | §103§112DP | Non-Final OA | — | Pending | Jan 12, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrime Bio Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jennifer E Graser has the most, with 1 of Prime Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.